Historical Petrol-Lead Emissions and Motor Neurone Disease Mortality in Australia: Evidence for a 20-Year Lag Relationship

Author and Affiliation

Mark A.S. Laidlaw, PhD (Independent Researcher)
Sydney, Australia
ORCID: https://orcid.org/0000-0001-7937-7844
Email: markas1968@gmail.com

Author Contributions
M.A.L. conceived the study, in collaboration with Chat GPT 5.0, compiled and analysed the data, prepared figures and tables, and wrote the manuscript. The author approved the final version of the paper and is solely responsible for its content.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The work was conducted independently by the author as part of ongoing research into historical environmental exposures and public health outcomes.

Competing Interests
The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethics Statement
This study used only publicly available, aggregated data on national petrol-lead emissions and age-standardised mortality from motor neurone disease (MND). No individual or identifiable human data were involved. Therefore, formal ethics approval and informed consent were not required in accordance with the National Health and Medical Research Council (NHMRC) National Statement on Ethical Conduct in Human Research (2007, updated 2018).

Competing Interests
The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment of AI Assistance

This manuscript benefited from the use of OpenAI's ChatGPT-5.0 (2025 edition)

Abstract

Background: Australia experienced one of the highest global per-capita exposures to petrol-derived lead (Pb) during the second half of the 20th century. Because lead accumulates in bone and is released slowly over decades, long-lag neurodegenerative effects are plausible but remain insufficiently explored at the population level. Motor neuron disease (MND) mortality has increased substantially in Australia since the 1980s, followed recently by an apparent plateau and emerging decline. Whether this long-term pattern aligns with the temporal dynamics of Australia's petrol-lead emissions has been previously partially assessed by Laidlaw et. al. (2015) and Zahran et al. (2017).

Methods: National age-standardised MND mortality rates (1986–2022) obtained from the Australian Institute of Health and Welfare (AIHW) were analysed alongside historical petrol-lead emissions shifted forward by 20 years to reflect latent neurotoxic processes. A cubic smoothing spline was used to characterise long-term MND mortality trends. Cumulative petrol-lead emissions shifted forward 20 years were examined to identify the plateau year corresponding to 99% of total historical emissions. A biologically informed projection model was developed using the WHO-estimated 23-year half-life of lead in bone to estimate future declines in MND mortality attributable to legacy skeletal lead.

Results: MND mortality increased steadily from 1986 and reached its highest levels around 2010–2012 before showing a modest decline thereafter. Forward-shifted cumulative petrol-lead emissions were strongly associated with national MND mortality (N = 37; r = 0.780; R^2 = 0.609; $F_{(1,35)}$ = 54.44; p = 1.25 × 10⁻⁸). The forward-shifted cumulative petrol-lead curve reached 99% of its total burden in 2017, corresponding to a

spline-estimated baseline MND ASR of 2.52. A 10-year extension of the spline-fitted MND mortality curve suggested a modest continuation of the post-2012 decline, and complementary exponential-decay scenarios based on 20–28-year skeletal lead half-lives produced trajectories of similar direction when anchored to the 2017 spline plateau. These descriptive models are not forecasts but indicate that observed recent declines are temporally compatible with both short-term continuation of current trends and long-lag reductions in historical skeletal lead burden. These findings suggest that the historical rise, peak, and emerging decline in MND mortality may be broadly compatible with the expected temporal profile of long-lag neurotoxicity from legacy petrol-lead exposure.

Conclusions: National MND mortality in Australia shows a long-term rise, peak, and gradual decline that aligns temporally with the rise and plateau of cumulative petrol-lead emissions when a biologically plausible lag structure is applied. Although ecological and non-causal by design, these findings highlight the need for mechanistic, toxicokinetic, and longitudinal individual-level research to evaluate whether legacy lead exposure contributes to the national MND burden and its potential future decline.

1. Introduction

Motor neurone disease (MND) is a progressive and fatal neurodegenerative disorder affecting both upper and lower motor neurons, resulting in weakness, paralysis, and eventual respiratory failure (Vans et al., 2017). Although a minority of cases are familial, most are sporadic and of unknown aetiology. Increasing evidence implicates environmental toxicants as potential contributors to disease risk, including exposure to heavy metals such as lead (Pb) (Meng et al., 2020; Wang et al., 2014). Lead readily crosses the blood–brain barrier, accumulates in bone and neural tissue, and is remobilised with age, providing a biologically plausible mechanism for delayed neurotoxic effects long after exposure has ceased (Hu et al., 1998; Rueben, 2018).

From the early 1930s until its phase-out in the early 2000s, the addition of tetraethyl lead to petrol generated a major anthropogenic source of airborne lead across Australia (Kristensen, L.J., 2015) and other industrialized nations such as the United States (Mielke et al., 2011). Emitted lead particles dispersed widely through urban atmospheres and settled into surface soils and household dust, creating a long-lived environmental reservoir. Despite dramatic reductions in airborne concentrations after the removal of leaded petrol, this historical legacy persists in urban soils and continues to influence human exposure (Laidlaw and Taylor, 2011; Laidlaw et al., 2014; Taylor et al., 2021; Thorsten et al, 2025).

A growing body of research has examined whether long-term population exposure to petrol-derived lead may contribute to neurological outcomes including MND. Laidlaw et al. (2015) reported strong temporal correlations between accumulated petrol-lead emissions and national MND mortality in Australia between 1962 and 2013, identifying an approximately 20-year lag between peak emissions and peak age-standardised death rates.

Building on this, Zahran et al. (2017) conducted cross-sectional age and state-level analyses showing that a one-percent increase in lifetime petrol-lead exposure corresponded to about a 0.3 percent increase in MND mortality, suggesting that Australia was approaching the peak of lead-related disease burden.

However, neither of these investigations had access to the full annual time series now available for both national petrol-lead emissions and officially recorded MND mortality. The present study extends their work by combining comprehensive emission data from 1958 to 2002 (Kristensen, 2015) with the Australian Institute of Health and Welfare's continuous age-standardised MND mortality data for 1986 to 2022. This allows explicit testing of temporal and lagged correlations to evaluate whether changes in MND mortality followed the historical trajectory of petrol-lead emissions. The analysis provides the first direct national-scale evidence that the decline in atmospheric lead exposure during the 1980s and 1990s was followed, roughly two decades later, by stabilisation and eventual decline in ages standardize MND mortality rates.

MND Individual Costs and Suffering

Motor neuron disease is one of the most devastating neurological conditions, imposing an extraordinary combination of medical costs, loss of income, caregiver burden, and profound human suffering. The disease relentlessly erodes mobility, speech, swallowing, breathing, and independence while leaving cognition largely intact, producing intense psychological distress. Individual lifetime financial costs often exceed AUD $500,000 to 2 million, and the emotional and social impacts extend deeply across families and communities. Even with modern treatments and multidisciplinary care, MND remains a

rapidly progressive and uniformly fatal disease that causes immense physical, emotional, and economic hardship.

Cost Estimates of MND in Australia

Motor neurone disease (amyotrophic lateral sclerosis, ALS) imposes an exceptionally high economic and societal burden. In Australia, a national cost-of-illness study commissioned by MND Australia estimated that the total cost of MND in 2015 was AUD $2.37 billion, comprising AUD $430.9 million in direct economic costs and AUD $1.94 billion in burden-of-disease costs, equivalent to approximately $1.1 million per person (Deloitte Access Economics, 2015). Updated modelling for MND Australia projects that the combined economic and burden-of-disease costs will reach AUD $5.02 billion in 2025, increasing to AUD $7.51 billion by 2050 if current care models remain unchanged (Evohealth, 2025).

2. Methods

Detailed methods include dataset descriptions, lag analysis framework, regression modelling, and statistical validation steps as outlined below.

2.1 Data Sources

Age-standardized MND mortality rate data for 1986–2022 were obtained from the Australian Institute of Health and Welfare (AIHW). Annual petrol-lead emissions data for 1958–2002 were sourced from Kristensen (2015), reconstructed from national fuel sales and lead content data.

2.2 Analytical Framework and Statistical Analysis

Analytical Framework and Statistical Analysis

The analytical approach combined (i) historical exposure reconstruction, (ii) latency-aligned cumulative emissions modelling, (iii) spline-based characterisation of national MND mortality trends, and (iv) statistical regression and projection models. These components were designed to evaluate whether the long-term rise, peak, and early decline in Australian MND mortality aligns temporally with the national legacy of petrol-derived lead (Pb) emissions under a biologically plausible latency and toxicokinetic framework.

Exposure–Outcome Alignment Framework

Historic Australian petrol-lead emissions were treated as an index of population-level lead exposure. Because petrol lead was emitted predominantly between the 1950s and early 2000s, and because skeletal lead exhibits a long residence time with decades-long release into blood, a 20-year forward shift was applied to cumulative petrol-lead emissions to approximate the expected population-level latency between peak exposure and disease manifestation. The concept is that Australians were continuously exposed to lead over this time which accumulated in their bones and then was released from their bones following the cessation of exposure to lead. This lag interval was chosen based on prior literature, toxicokinetic principles, and exploratory Pearson correlations indicating maximal alignment at approximately 20 years.

The lagged cumulative petrol-lead series was then merged with national age-standardised MND mortality rates for the period 1986–2022 (N = 37), enabling direct comparison of exposure accumulation with subsequent disease trends.

Spline Trend Modelling of MND Mortality

Because national MND mortality exhibits a gradual rise, peak, and decline over multi-decadal scales, a cubic smoothing spline was applied to ASR values to visualise and characterise long-term non-linear patterns. This spline approach does not impose a parametric form on the temporal trajectory and provides a stable estimate of ASR at any given year, including the cumulative petrol-lead plateau year. The spline-estimated baseline ASR at the plateau of lagged cumulative petrol-lead burden (identified as 2017) was 2.52.

Linear Regression Analysis (Excel ToolPak)

Inferential statistics were conducted using Microsoft® Excel® for Microsoft 365 MSO (Version 2510 Build 16.0.19328.20190) 64-bit with the Data Analysis ToolPak. A simple linear regression model was fitted with:

- Dependent variable: National MND age-standardised mortality rate (ASR)

- Independent variable**:** Forward-shifted cumulative petrol-lead burden (20-year lag)

The Excel Data Analysis Regression function generated the regression coefficients, ANOVA table, and significance values. This model demonstrated a strong and highly statistically significant association between lagged cumulative petrol-lead emissions and MND ASR:

- Multiple R = 0.780

- R² = 0.609

- Adjusted R² = 0.598

- F(1,35) = 54.44

- p = 1.25×10^{-8}

- N = 37 observations

Residuals were evaluated visually using scatterplots and standardised residual-versus-predicted plots generated in Excel to ensure homoscedasticity and approximate normality.

Identification of Cumulative Exposure Plateau

Cumulative petrol-lead emissions were examined to determine the year at which 99% of total historical emissions had accumulated. When shifted forward 20 years, this plateau occurred in 2017, marking the year beyond which additional cumulative exposure contributes minimally to long-term burden. This year was used as the reference point for the half-life toxicokinetic modelling.

Spline Trend Modelling of MND Mortality

To characterize medium-term patterns in national MND mortality, a cubic regression spline was fitted to annual ASR values (1986–2022). The spline provided a smooth representation of long-term curvature and enabled estimation of a locally weighted trend

with 95% confidence intervals. The fitted curve showed a gentle easing after 2012 and stabilized around 2017, which corresponded to the year in which the forward-shifted cumulative petrol-lead indicator (20-year lag) had reached approximately 99% of its historical maximum. The spline was extended for an additional ten years (2022–2032) to illustrate the trajectory implied by continuation of recent trends; this projection was descriptive only and not interpreted as a forecast.

Half-Life Toxicokinetic Projection Model

To assess long-lag toxicokinetic plausibility, three exponential-decay scenarios were constructed using skeletal lead half-lives of 20, 23, and 28 years. The 23 year half-life of lead in bone consistent was obtained by WHO (2021). . Each decay curve was anchored to the spline-estimated ASR in 2017, the year marking the plateau of cumulative petrol-lead burden. The resulting trajectories represent conceptual exposure-clearance patterns rather than predictive mortality models. Across the three half-life scenarios, projected ASR values fell within ranges compatible with the direction and magnitude of the observed post-2012 decline, providing a mechanistically informed context for interpreting the emerging downturn in national MND mortality.

3. Results

Temporal trends in national MND mortality (1986–2022)

Age-standardised MND mortality rates (ASR) increased steadily from 1986 through the early 2000s, rising from 1.74 per 100,000 in 1986 to a peak of 2.74 per 100,000 in 2011, with similarly elevated values in 2010 and 2012. Beginning after 2012, a modest but

consistent decline was observed, with ASR values stabilising between 2.26 and 2.40 during 2017–2022. A cubic smoothing spline characterised the long-term pattern as a gradual rise followed by a distinct plateau and early downward inflection (Figure 3).

Figure 1. Cumulative Australian petrol lead emissions (tonnes) (1986–2022) and annual petrol-lead emissions (tonnes) (1958–2002).

The left y-axis shows cumulative petrol lead emissions (tonnes; thin red line) the right y-axis shows annual petrol-lead emissions (tonnes; thin black line). Emissions peaked mid-1970s and declined rapidly after the phase-out of leaded petrol. The rise in MND mortality follows by about 20 years.

Sources: AIHW (1986–2022); Kristensen (2015).

Cumulative petrol-lead emissions and lag alignment

Forward-shifted cumulative national petrol-lead emissions (20-year lag) rose sharply from the 1950s through the late 1990s and then approached a stable plateau. When shifted forward by 20 years to approximate latency, the cumulative petrol-lead curve reached 99% of its total burden in 2017, marking the point at which additional accumulation becomes negligible. This plateau year corresponded closely with the beginning of the stabilised and modestly declining phase of national MND ASR. The spline-estimated MND ASR at the plateau year was 2.52.

Association between lagged cumulative petrol-lead burden and MND mortality

To quantify the strength of the long-term association between petrol-lead exposure burden and MND mortality, a simple linear regression was conducted using ASR as the dependent variable and the 20-year forward-shifted cumulative petrol-lead burden as the predictor (N = 37). The model demonstrated a strong and highly statistically significant association (Multiple R = 0.780; R^2 = 0.609; Adjusted R^2 = 0.598). The regression slope differed significantly from zero (F(1,35) = 54.44; $p = 1.25 \times 10^{-8}$). Thus, approximately 61% of the year-to-year variation in national MND ASR over 1986–2022 can be statistically accounted for by cumulative petrol-lead burden when shifted forward by 20 years.

Figure 2. Association between lagged petrol-lead emissions and MND mortality in Australia.

Scatterplot with 20-year lag regression line (solid). Correlation: $R^2 = 0.72$, $p < 0.001$.

Sources: AIHW; Kristensen (2015).

Although this model is ecological and not causal, the magnitude and significance of the association reflect the strong temporal concordance between cumulative petrol-lead exposure and the rise and peak of national MND mortality.

Projected Spline Model

Figure 3. Historical and projected relationships between cumulative petrol lead and motor neurone disease (MND) mortality in Australia. (A) Historical associations between forward-shifted cumulative petrol-lead emissions (20-year lag, left axis) and age-standardized MND mortality (points, right axis) with spline-smoothed trend and 95% confidence interval (blue line and shaded band). The lagged cumulative petrol-lead curve

rises steeply from the late 1950s through the 1980s and approaches its asymptote (~99% of total historical burden) by 2017. The spline-fitted MND mortality curve shows a gradual easing after 2012 and flattens near 2017. (B) Descriptive projections extending the spline and incorporating skeletal-lead toxicokinetics. A short-term extension of the spline (dotted green line, 2022–2032) illustrates the trajectory implied by continuation of the 2012–2022 trend, with a widening 95% confidence interval (green shading). Three exponential-decay scenarios (dashed lines) anchored to the 2017 spline value model the multi-decadal clearance of skeletal lead using half-lives of 20, 23, and 28 years. These projections are mechanistic scenarios rather than statistical forecasts but provide context for interpreting the emerging post-2012 decline in national MND mortality.

The spline-smoothed MND mortality curve (1986–2022) showed a gradual easing after 2012, followed by a period of relative stability around 2017. To examine the short-term implications of this pattern, the fitted spline and its 95% confidence interval were extended forward by ten years (2022–2032). This descriptive projection illustrates the trajectory implied by continuation of recent trends and suggests a modest downward drift, although the confidence interval widens when the spline is extrapolated beyond the observed data range. The purpose of this exercise is interpretive rather than predictive; it provides a reference against which to compare toxicokinetic scenarios rather than a forecast of future mortality.

Half-Life Toxicokinetic Projection of Future MND Mortality

Three exponential-decay scenarios were developed using skeletal lead half-lives of 20, 23, and 28 years, anchored to the spline-estimated ASR at 2017, the year in which the

lagged cumulative petrol-lead indicator reached approximately 99% of its historical maximum. These scenarios describe conceptual long-lag clearance of historical skeletal lead burden rather than predictive mortality trajectories. Across the three half-life assumptions, the resulting curves show gradual multi-decadal declines that fall within ranges broadly consistent with the emerging downturn in MND mortality following 2012. Although the timing and magnitude differ by half-life, all scenarios reflect the slow dynamics expected for lead stored in adult bone and provide a mechanistic frame for interpreting the observed easing in national mortality rates.

Summary of key findings

Overall, the results show:

1. Spline modelling of national MND mortality (1986–2022) demonstrated a gradual easing after 2012, with the fitted curve flattening near 2017, the point at which the 20-year-lagged cumulative petrol-lead indicator reached roughly 99% of its historical maximum.

2. A descriptive 10-year extension of the spline trend (2022–2032) suggested a continuation of this modest downward trajectory, although uncertainty increased with distance from the observed data range.

3. Three mechanistic toxicokinetic scenarios, based on skeletal lead half-lives of 20, 23, and 28 years, were anchored to the spline-estimated ASR at 2017 and generated gradual multi-decadal exponential-decay curves.

4. Despite differing decay rates, all half-life scenarios produced trajectories that were directionally consistent with the observed post-2012 decline in national MND mortality.

5. Taken together, the spline projection and the long-lag half-life scenarios provide complementary descriptive perspectives, one reflecting the continuation of recent empirical trends, the other illustrating the slow clearance dynamics of historical skeletal lead burden—that help contextualise the emerging reduction in MND mortality.

These findings collectively suggest that Australia's rise, peak, and emerging decline in MND mortality are temporally compatible with long-term consequences of legacy petrol-lead exposure and its gradual post-plateau decay.

4. Discussion

4.1 Comparison with Previous Work

The findings of this national time-series analysis build upon and extend two key prior investigations linking lead exposure and MND mortality in Australia (Laidlaw et al., 2015) first demonstrated a strong association between cumulative historical petrol-lead emissions and age-standardised MND death rates, identifying an optimal twenty-year lag. Zahran et al. (2017) expanded this work by applying cross-sectional models showing a proportional relationship between cumulative lead exposure and MND mortality. The present study advances both studies by providing direct longitudinal validation, demonstrating that the

decline in petrol-lead emissions was followed by stabilisation of MND mortality approximately two decades later.

The pattern described in this study, rising MND mortality during decades of increasing petrol-lead emissions, stabilisation as cumulative emissions approach their maximum, and a subsequent modest decline is highly consistent with the toxicokinetic properties of lead and its long residence time in bone. By shifting cumulative petrol-lead emissions forward by 20 years to reflect the empirically observed lag between emissions and MND mortality, the cumulative curve plateaued in the early 2000s, indicating that Australia's petrol-derived lead burden had effectively ceased rising after that time. This plateau aligns closely with the period in which the age-standardised MND mortality rate also stabilised, followed by a shallow but detectable downward trend over 2010–2022.

Figure 3 illustrates two complementary descriptive modelling approaches that help contextualise the emerging decline in national MND mortality. First, a short-term projection extending the spline-fitted ASR curve for ten years (2022–2032) showed a modest continuation of the post-2012 easing trend, although with widening uncertainty beyond the observed data range. Second, a set of long-lag toxicokinetic scenarios was developed using skeletal lead half-lives of 20, 23, and 28 years, each anchored to the spline-estimated ASR in 2017, the year in which the 20-year-lagged cumulative petrol-lead indicator had reached approximately 99% of its total historical burden. Because adult bone stores more than 90% of retained lead and releases it slowly back into circulation over decades, these half-life scenarios represent plausible biological clearance profiles rather than predictive mortality forecasts. Across all three half-life assumptions, the resulting exponential-decay curves produced gradual multi-decadal declines broadly

aligned in direction with the observed post-2012 downturn in MND ASR. Although inherently non-predictive, these mechanistic scenarios provide a coherent toxicological context in which slow reductions in historical skeletal lead burden could contribute to the long-term stabilization and early decline now emerging in national MND mortality.

These findings reinforce and extend the earlier ecological evidence provided by Laidlaw et al. (2015), who first identified temporal alignment between rising historical lead exposure and increasing MND mortality, and by Zahran et al. (2017), who predicted future declines in MND risk following the elimination of petrol lead using a cohort-based modelling framework. The present analysis contributes substantially by leveraging a longer 37-year national mortality series, incorporating updated petrol-lead emissions data, and using a toxicokinetic half-life model to anchor the expected decline to a biological mechanism (skeletal lead turnover) rather than to emissions-driven regression alone. The consistency among these independent analytical approaches emissions lag model, cumulative exposure plateau, and half-life decay, strengthens the argument that legacy lead exposure may play a role in the temporal dynamics of MND mortality in Australia.

It is important to emphasise, however, that these associations cannot by themselves establish causality. Ecological exposure metrics such as national petrol-lead emissions and cumulative atmospheric lead burdens cannot account for individual-level variability in exposure pathways, genetic susceptibility, occupational factors, or smoking, alcohol, or other environmental neurotoxins that may confound or interact with lead exposure. MND diagnosis and coding practices have also evolved over time, although the stability of coding standards in Australia since the mid-2000s reduces the likelihood that diagnostic drift explains the observed recent decline. The half-life scenario, while toxicologically

grounded, remains dependent on assumptions about the relationship between skeletal lead turnover and MND risk, which cannot be confirmed without individual-level biomarker data (e.g., bone lead measured via K-XRF).

Modelling results further clarify how multiple independent temporal patterns align without implying causality. First, national MND mortality rose during decades of increasing petrol-lead emissions; second, mortality stabilized around 2017, the same period in which the 20-year-lagged cumulative petrol-lead indicator reached roughly 99% of its historical maximum; and third, both the short-term spline projection (2022–2032) and the long-lag exponential-decay scenarios based on 20-, 23-, and 28-year skeletal lead half-lives produced trajectories that were directionally consistent with the emerging post-2012 decline. Although these models are descriptive and not predictive, the convergence of these temporal structures raises the possibility that legacy lead exposure could have contributed to long-term national patterns in MND mortality. If correct, this would have implications for international comparisons: countries that phased out petrol lead earlier would be expected to reach their cumulative-lead plateau sooner and might therefore exhibit earlier or more pronounced easing in MND mortality.

Nonetheless, the alignment of three independent temporal patterns: (1) increasing MND mortality during rising petrol-lead emissions, (2) stabilisation of MND mortality when cumulative petrol-lead plateaus, and (3) emerging declines consistent with skeletal lead clearance, raises the possibility that legacy lead exposure may have contributed to long-term national trends in MND mortality. If correct, this would carry important public health implications. It would suggest that countries eliminating petrol lead earlier may see earlier or more pronounced declines in MND mortality, while countries still experiencing

substantial lead exposure from other sources (e.g., lead paint, lead plumbing, contaminated soils) may not.

Future research integrating individual-level biomarkers of cumulative lead exposure, especially bone lead measured by K-XRF, with longitudinal neurological outcomes would allow for more direct investigation of the potential causal pathways suggested by this ecological evidence. Additionally, analyses incorporating regional variation in historical petrol-lead exposure, soil lead contamination, or occupational lead burdens may help further clarify the contribution of lead to MND risk in different Australian populations.

4.2 Strengths and Limitations

Strengths

This study has several notable strengths. First, it draws on the longest available national mortality series for MND in Australia (1986–2022), allowing examination of multi-decadal patterns rather than short-interval snapshots. Second, the analysis benefits from an updated and internally consistent historical petrol-lead emissions inventory (Kristensen), used both in lagged annual form and in cumulative form to identify the plateau in national lead burden. Third, the study integrates and triangulates three analytically distinct approaches: (1) an empirical 20-year lag model linking annual petrol-lead emissions to national MND mortality, (2) examination of the plateau in the 20-year-lagged cumulative petrol-lead curve—which reached approximately 99% of its historical maximum around 2017—and (3) descriptive modelling incorporating a spline-based extension of recent mortality trends and three mechanistic toxicokinetic scenarios based on skeletal lead half-lives of 20, 23, and 28 years. The consistency in directionality across these independent methods

strengthens the internal coherence of the temporal associations observed. Fourth, the toxicokinetic scenarios provide a biologically informed framework for interpreting the emerging post-2012 easing in MND mortality, complementing the empirical spline-based trend analysis. Finally, the national-level approach avoids regional inconsistencies in reporting and offers a clear temporal signal suitable for hypothesis generation and international comparison.

Limitations

This study also has important limitations. As an ecological analysis, it cannot assess individual-level exposure, susceptibility, or outcome information, nor can it establish causality. National petrol-lead emissions represent population-wide environmental exposure rather than personal dose, and factors such as occupation, lifestyle, socioeconomic conditions, genetic predisposition, and exposure to other neurotoxicants (e.g., pesticides, solvents, metals) may confound or interact with lead exposure but cannot be accounted for using ecological data. Bone lead—the key long-term biomarker relevant to the half-life modelling—was not available for individuals and could not be measured directly.

The exponential-decay scenarios based on skeletal lead half-lives of 20, 23, and 28 years, although toxicologically plausible, remain conceptual and should not be interpreted as predictive mortality models. Similarly, the definition of the cumulative petrol-lead "plateau" year (≈99% of historical burden) is operational and introduces some imprecision into the selection of the model anchor point. While MND coding in Australia has been stable since the mid-2000s, earlier diagnostic and classification changes may introduce

minor artefacts into long-term trend estimation. Finally, this study does not capture potential contributions from non-petrol sources of lead exposure (e.g., lead paint, plumbing, industrial emissions, legacy soil contamination), which may influence MND risk independently of petrol-derived lead.

Overall assessment

Taken together, these strengths and limitations indicate that the observed temporal pattern—rising MND mortality during increasing petrol-lead emissions, stabilization when lagged cumulative exposure approaches its plateau, and a modest post-2012 decline consistent with the direction of both short-term spline projections and long-lag skeletal lead clearance—should be interpreted cautiously. These findings do not establish causality, but they outline a coherent temporal structure that warrants further investigation using individual-level biomarkers (particularly bone lead measured by K-XRF), improved exposure reconstruction, and spatially resolved epidemiological studies to determine whether historical lead exposure may contribute to MND risk at the population level.

5. Conclusions

This study provides new evidence that long-term national trends in motor neurone disease (MND) mortality in Australia align temporally with historical patterns of petrol-lead emissions and the expected toxicokinetics of skeletal lead. MND mortality increased during the decades in which petrol-lead emissions were rising, stabilised when forward-shifted cumulative petrol-lead exposure approached its plateau, and has shown a modest decline since the early 2010s. The integration of both short-term spline projections and long-lag half-life scenarios (20, 23, and 28 years), anchored to the 2017 spline plateau,

further demonstrates that the direction of the recent easing in mortality is compatible with the slow clearance dynamics of historical skeletal lead burdens.

While these findings do not establish causality, the convergence of multiple independent analytical approaches—including empirical lag modelling, plateau analysis, spline-based trend estimation, and mechanistic half-life scenarios—strengthens the plausibility of a relationship between legacy lead exposure and long-term MND mortality patterns. These results highlight the need for individual-level studies using direct biomarkers of cumulative lead exposure, particularly bone lead measured by K-XRF, along with more granular environmental and clinical data. Such efforts will be crucial for determining whether lead contributes causally to MND risk and for assessing whether the emerging decline in MND mortality is likely to continue as legacy skeletal lead stores diminish over time.

References

Australian Institute of Health and Welfare (AIHW). (2023). *General Record of Incidence of Mortality (GRIM) Data Cubes: Motor Neurone Disease (ICD-10 G12.2), 1986–2022.* Canberra: AIHW. Available at: https://www.aihw.gov.au/

Deloitte Access Economics. *Economic analysis of motor neurone disease (MND) in Australia.* Canberra: MND Australia; 2015.

Evohealth; MND Australia. *Every moment matters: Addressing the human and economic toll of motor neurone disease in Australia.* Canberra; July 2025.

Hu H, Rabinowitz M, Smith D. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. Environ Health Perspect. 1998 Jan;106(1):1–8. https://doi.org/10.1289/ehp.981061.

Kristensen LJ. Quantification of atmospheric lead emissions from 70 years of leaded petrol consumption in Australia. Atmospheric Environment. 2015 Jun 1;111:195-201. https://doi.org/10.1016/j.atmosenv.2015.04.012

Laidlaw MA, Rowe DB, Ball AS, Mielke HW. A temporal association between accumulated petrol (gasoline) lead emissions and motor neuron disease in Australia. International journal of environmental research and public health. 2015 Dec;12(12):16124-35. https://doi.org/10.3390/ijerph121215047

Laidlaw MAS, Taylor MP. Potential for childhood lead poisoning in the inner cities of Australia due to exposure to lead in soil dust. *Environmental Pollution.* 2011;159(1):1–9. https://doi.org/10.1016/j.envpol.2010.08.020

Mielke HW, Laidlaw MA, Gonzales CR. Estimation of leaded (Pb) gasoline's continuing material and health impacts on 90 US urbanized areas. Environment international. 2011 Jan 1;37(1):248-57. https://doi.org/10.1016/j.envint.2010.08.006

Laidlaw MA, Zahran S, Pingitore N, Clague J, Devlin G, Taylor MP. Identification of lead sources in residential environments: Sydney Australia. Environmental pollution. 2014 Jan 1;184:238-46. https://doi.org/10.1016/j.envpol.2013.05.007

Meng E, Mao Y, Yao Q, Han X, Li X, Zhang K, Jin W. Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2020 Jan;41(1):35-40. https://doi.org/10.1007/s10072-019-04067-z.

Reuben A. Childhood lead exposure and adult neurodegenerative disease. *J Alzheimers Dis.* 2018;64(1):17–42. https://doi.org/10.3233/JAD-180267.

Taylor MP, Isley CF, Fry KL, Liu X, Gillings MM, Rouillon M. A citizen science approach to identifying trace metal contamination risks in urban gardens. *Environment International.* 2021;155:106582. https://doi.org/10.1016/j.envint.2021.106582

Thorstenson R, Montgomery J, Klimas C. What's in your soil? A citywide investigation of the importance of soil lead for predicting elevated blood lead levels in Chicago. GeoHealth. 2025 Oct;9(10):e2025GH001572. https://doi.org/10.1029/2025GH001572

Van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, Van den Berg LH. Amyotrophic lateral sclerosis. The Lancet. 2017 Nov 4;390(10107):2084-98.

 https://www.who.int/10.1016/S0140-6736(17)31287-4

Wang MD, O'Reilly EJ, Weisskopf MG, Logroscino G, McGuire V, Ni J, et al. A meta-analysis of observational studies of the association between chronic occupational exposure to lead and amyotrophic lateral sclerosis. J Occup Environ Med. 2014 Dec;56(12):1235-42. https://www.who.int/10.1097/JOM.0000000000000347.

World Health Organization. WHO guideline for clinical management of exposure to lead [Internet]. Geneva: World Health Organization; 2021. 105 p. Available from: https://www.who.int/publications/i/item/9789240037045

Zahran S, Laidlaw MA, Rowe DB, Ball AS, Mielke HW. Motor neuron disease mortality and lifetime petrol lead exposure: evidence from national age-specific and state-level age-standardized death rates in Australia. Environmental research. 2017 Feb 1;153:181-90. https://doi.org/10.1016/j.envres.2016.11.023

Supplementary Information

S1. Data Sources

Table S0. Overview of source datasets.

Dataset	Variable	Time Span	Source / Citation	Notes
Petrol-lead emissions (Australia)	Annual and cumulative emissions	1958–2002	Kristensen (2015), Atmospheric Environment 111:195–201	Used for Figures and lag analyses
MND mortality (AIHW)	Age-standardized mortality rate (ASR)	1986–2022	Australian Institute of Health and Welfare (AIHW), cause-of-death statistics	Used for Figures, regression and projection
Derived lag dataset	Persons_ASR vs Lead_cumulative_(Year−20)	1986–2002	Constructed in this study from Kristensen (2015) and AIHW	Used for regression and projection

S2. Raw Data Tables

Table S1. Kristensen (1958–2002) Australian petrol-lead emissions (tonnes).

Year	Australia	NSW	VIC	QLD	SA	TAS	WA	NT	Cumulative_Emissions
1958	3,028.7	1,032.5	933.0	413.2	316.4	101.3	224.9	7.4	3,028.7
1959	3,267.9	1,116.7	1,004.9	450.1	338.7	108.8	240.7	7.9	6,296.6
1960	3,546.3	1,228.2	1,097.1	482.3	354.6	116.4	258.7	8.9	9,842.9
1961	3,689.2	1,287.3	1,128.3	498.1	373.1	119.1	273.0	10.1	13,532.1
1962	3,959.9	1,390.3	1,196.7	538.9	398.5	128.0	296.7	10.8	17,492.0
1963	4,243.7	1,485.7	1,282.8	575.9	427.7	137.5	322.3	11.8	21,735.7
1964	4,604.1	1,611.7	1,377.8	636.2	465.8	147.2	351.9	13.5	26,339.8
1965	4,884.3	1,704.7	1,453.5	677.4	498.3	157.6	379.5	13.4	31,224.1
1966	5,073.5	1,765.3	1,505.7	707.7	508.8	163.7	407.7	14.7	36,297.6
1967	5,350.3	1,864.5	1,578.9	744.6	530.5	173.8	441.1	16.9	41,647.9
1968	5,660.2	1,978.5	1,660.4	787.1	546.8	180.6	485.7	21.2	47,308.1
1969	6,060.1	2,106.5	1,757.8	849.9	587.7	189.6	538.5	30.2	53,368.2
1970	6,412.6	2,245.8	1,853.3	893.6	605.9	196.3	580.2	37.4	59,780.8
1971	6,744.9	2,375.4	1,945.7	941.9	625.3	202.8	612.2	41.7	66,525.7
1972	7,075.3	2,469.3	2,058.7	1,007.2	648.6	211.3	635.0	45.2	73,601.0
1973	7,615.8	2,631.8	2,188.9	1,124.9	706.9	227.0	688.1	48.3	81,216.8
1974	7,869.1	2,716.5	2,240.2	1,155.5	751.6	234.5	718.6	52.1	89,085.9
1975	7,034.5	2,322.4	1,664.5	1,231.6	770.7	237.8	755.1	52.4	96,120.4
1976	7,207.8	2,379.6	1,761.8	1,288.8	764.3	189.4	765.1	59.0	103,328.2
1977	6,751.0	2,038.1	1,505.6	1,358.0	811.1	154.7	822.1	61.4	110,079.2
1978	6,941.7	2,075.4	1,554.8	1,424.4	816.3	157.1	851.4	62.4	117,020.9
1979	6,909.9	2,116.8	1,420.4	1,489.6	812.9	144.0	859.5	66.7	123,930.8
1980	6,793.8	1,986.1	1,394.0	1,500.8	850.3	143.3	850.3	69.0	130,724.6
1981	6,851.6	2,005.0	1,419.4	1,573.6	780.6	141.0	859.5	72.5	137,576.2
1982	6,893.4	1,975.8	1,444.5	1,664.8	794.8	137.7	803.8	71.9	144,469.6
1983	6,871.7	1,981.4	1,425.0	1,604.5	793.1	136.4	857.0	74.3	151,341.3

Year	Australia	NSW	VIC	QLD	SA	TAS	WA	NT	Cumulative_Emissions
1984	6,380.3	2,018.9	976.3	1,682.7	668.4	142.8	813.7	77.5	157,721.6
1985	6,314.2	2,005.5	980.1	1,686.2	666.3	144.5	749.1	82.6	164,035.8
1986	6,096.5	1,939.3	951.8	1,654.8	655.3	142.0	669.7	83.5	170,132.3
1987	5,898.5	1,828.7	906.5	1,570.3	624.0	133.1	758.3	77.5	176,030.8
1988	5,688.6	1,750.7	870.4	1,573.5	598.7	129.0	694.5	71.8	181,719.4
1989	5,394.1	1,616.8	830.9	1,521.4	573.3	126.1	658.8	66.8	187,113.5
1990	4,925.3	1,463.5	748.9	1,393.6	522.2	120.4	612.7	63.9	192,038.8
1991	4,494.0	1,335.9	673.8	1,288.4	475.8	111.2	551.2	57.8	196,532.8
1992	4,247.3	1,245.1	632.0	1,238.0	454.5	106.2	516.3	55.3	200,780.1
1993	3,757.8	1,148.1	599.1	1,173.9	351.8	101.6	332.9	50.3	204,537.9
1994	2,055.5	561.8	423.8	495.0	219.4	82.7	252.0	20.8	206,593.4
1995	1,066.3	233.1	208.9	258.4	127.2	57.3	162.1	19.3	207,659.7
1996	847.0	225.1	188.9	187.3	111.7	36.0	89.3	8.7	208,506.7
1997	740.8	190.5	165.6	164.9	100.8	32.6	78.6	7.8	209,247.5
1998	502.4	142.0	132.5	102.4	47.8	18.9	52.3	6.6	209,749.9
1999	427.2	115.4	112.2	90.7	41.9	16.8	44.6	5.6	210,177.1
2000	333.6	88.6	87.8	73.6	33.8	14.0	31.7	4.1	210,510.7
2001	237.6	66.5	70.0	58.8	26.5	11.8	0.8	3.0	210,748.3
2002	98.8	26.4	30.1	24.4	11.5	5.1	0.3	0.8	210,847.1

Table S2. AIHW age-standardised MND mortality (1986–2022).

Year	Male_ASR	Female_ASR	Persons_ASR
1986	2.0	1.6	1.7
1987	2.2	1.7	1.9
1988	2.9	1.4	2.0
1989	2.7	1.9	2.2
1990	2.7	1.5	2.0
1991	2.3	1.6	1.8
1992	2.6	1.7	2.1
1993	2.7	1.6	2.1
1994	2.8	1.7	2.2
1995	2.8	1.8	2.2
1996	2.8	1.4	2.0
1997	2.2	2.0	2.1
1998	3.0	2.0	2.4
1999	3.1	1.8	2.4
2000	3.1	2.0	2.4
2001	3.3	1.8	2.4
2002	3.3	1.9	2.5
2003	3.0	2.3	2.6
2004	2.9	2.1	2.5
2005	2.9	2.0	2.4
2006	3.0	2.1	2.5
2007	3.3	2.1	2.7
2008	3.2	2.2	2.7
2009	3.3	1.9	2.6
2010	3.3	2.2	2.7

Year	Male_ASR	Female_ASR	Persons_ASR
2011	3.4	2.1	2.7
2012	3.3	2.1	2.7
2013	3.2	2.3	2.8
2014	2.7	1.8	2.3
2015	3.1	2.1	2.5
2016	3.0	2.2	2.6
2017	2.6	2.0	2.3
2018	2.8	1.9	2.4
2019	3.1	2.2	2.6
2020	3.0	1.8	2.4
2021	3.0	1.9	2.4
2022	3.0	1.8	2.4

Year	Male_ASR	Female_ASR	Persons_ASR

Table S3. Derived dataset for 20-year lag regression (1986–2002).

Year	MND Persons_ASR	Lead_cumulative_(Year+ 20) (tonnes)
1978	NA	3028.7
1979	NA	6296.6
1980	NA	9842.9
1981	NA	13532.1
1982	NA	17492
1983	NA	21735.7
1984	NA	26339.8
1985	NA	31224.1
1986	1.7	36,297.6
1987	1.9	41,647.9
1988	2.0	47,308.1
1989	2.2	53,368.2
1990	2.0	59,780.8
1991	1.8	66,525.7
1992	2.1	73,601.0
1993	2.1	81,216.8
1994	2.2	89,085.9
1995	2.2	96,120.4
1996	2.0	103,328.2
1997	2.1	110,079.2
1998	2.4	117,020.9
1999	2.4	123,930.8
2000	2.4	130,724.6
2001	2.4	137,576.2

Year	MND Persons_ASR	Lead_cumulative_(Year+ 20) (tonnes)
2002	2.5	144,469.6
2003	2.6	151341.3
2004	2.5	157721.6
2005	2.4	164035.8
2006	2.5	170132.3
2007	2.7	176030.8
2008	2.7	181719.4
2009	2.6	187113.5
2010	2.7	192038.8
2011	2.7	196532.8
2012	2.7	200780.1
2013	2.8	204537.9
2014	2.3	206593.4
2015	2.5	207659.7
2016	2.6	208506.7
2017	2.3	209247.5
2018	2.4	209749.9
2019	2.6	210177.1
2020	2.4	210510.7
2021	2.4	210748.3
2022	2.4	210847.1

S3. References for Supplementary Data

Kristensen, L.J. (2015). Quantification of atmospheric lead emissions from 70 years of leaded petrol consumption in Australia. Atmospheric Environment, 111, 195–201. https://doi.org/10.1016/j.atmosenv.2015.04.022

Australian Institute of Health and Welfare (AIHW). Motor neurone disease mortality statistics (1986–2022). Canberra: AIHW.